ANI Pharmaceuticals, Inc. Share Price

Equities

ANIP

US00182C1036

Pharmaceuticals

Market Closed - Nasdaq 01:30:00 27/04/2024 am IST 5-day change 1st Jan Change
65.36 USD +0.63% Intraday chart for ANI Pharmaceuticals, Inc. -0.18% +18.53%
Sales 2024 * 535M 44.59B Sales 2025 * 576M 48B Capitalization 1.37B 114B
Net income 2024 * 22M 1.83B Net income 2025 * 34M 2.84B EV / Sales 2024 * 2.41 x
Net cash position 2024 * 80.28M 6.7B Net cash position 2025 * 188M 15.66B EV / Sales 2025 * 2.06 x
P/E ratio 2024 *
50.8 x
P/E ratio 2025 *
31.8 x
Employees 642
Yield 2024 *
-
Yield 2025 *
-
Free-Float 80.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.63%
1 week-0.18%
Current month-5.45%
1 month-5.45%
3 months+19.62%
6 months+11.01%
Current year+18.53%
More quotes
1 week
64.29
Extreme 64.29
66.90
1 month
64.20
Extreme 64.2
69.02
Current year
53.47
Extreme 53.4746
70.81
1 year
37.40
Extreme 37.4
70.81
3 years
22.31
Extreme 22.31
70.81
5 years
22.31
Extreme 22.31
86.96
10 years
22.31
Extreme 22.31
86.96
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 08/20/08
Director of Finance/CFO 53 06/16/06
Chairman 63 17/18/17
Members of the board TitleAgeSince
Director/Board Member 60 01/18/01
Director/Board Member 66 06/20/06
Director/Board Member 68 01/18/01
More insiders
Date Price Change Volume
26/24/26 65.36 +0.63% 67,172
25/24/25 64.95 -0.73% 82,931
24/24/24 65.43 -1.07% 83,439
23/24/23 66.14 +0.79% 85,940
22/24/22 65.62 +0.21% 95,322

Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST

More quotes
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
65.36 USD
Average target price
79.8 USD
Spread / Average Target
+22.09%
Consensus